69638-06-8

Basic information

• Product Name: 2-bromo-1-(4-hydroxy-3-methoxyphenyl)ethanone
• Synonyms: 2-bromo-1-(4-hydroxy-3-methoxyphenyl)ethanone
• CAS NO: 69638-06-8
• Molecular Formula: C₉H₉BrO₃
• Molecular Weight: 245.06996
• EINECS: 604-604-1
• Mol File: 69638-06-8.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 356.1°C at 760 mmHg
• Flash Point: 169.1°C
• Appearance: /
• Density: 1.565g/cm³
• Vapor Pressure: 1.46E-05mmHg at 25°C
• Refractive Index: 1.586
• CAS DataBase Reference: 2-bromo-1-(4-hydroxy-3-methoxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-(4-hydroxy-3-methoxyphenyl)ethanone(69638-06-8)
• EPA Substance Registry System: 2-bromo-1-(4-hydroxy-3-methoxyphenyl)ethanone(69638-06-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 69638-06-8(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 68, p. 1913, 1946 DOI: 10.1021/ja01214a013

InChI:InChI=1/C9H9BrO3/c1-13-9-4-6(8(12)5-10)2-3-7(9)11/h2-4,11H,5H2,1H3

Upstream product

• 90-05-1 2-methoxy-phenol 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 113951-03-4 1-(4-hydroxy-3-methoxy-phenyl)-2-thiocyanato-ethanone 
• 306-08-1 Homovanillic acid 
• 18256-48-9 2,4'-dihydroxy-3'-methoxyacetophenone 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 284043-11-4 4-amino-butyric acid 2-(4-hydroxy-3-methoxy-phenyl)-2-oxo-ethyl ester 
• 125629-04-1 ethyl (3,4-dihydroxy-5-nitrobenzoyl)carboxylate 
• 125629-37-0 ethyl (4-hydroxy-3-methoxy-5-nitrobenzoyl)carboxylate 
• 134610-77-8 2-methoxy-6-nitro-4-(quinoxalin-2-yl)phenol 
• 1147548-93-3 2-(4'-hydroxy-3'-methoxyphenyl)-6-iodoimidazo[1,2-a]pyridine 
• 1195384-16-7 2-(4-benzyloxy-3-methoxyphenyl)imidazo[1,2-a]pyrimidine 
• 2785-87-7 2-methoxy-4-n-propylphenol 
• 2785-89-9 4-Ethylguaiacol 
• 7382-59-4 guaiacylglycerol-β-guaiacyl ether 
• 22317-34-6 β-hydroxy-α-(2-methoxyphenoxy)4-hydroxy-3-methoxypropiophenone 

Relevant articles and documents

Nucleus-independent chemical shift (NICS) as a criterion for the design of new antifungal benzofuranones

The assertion made by Wu et al. that aromaticity may have considerable implications for molecular design motivated us to use nucleus-independent chemical shifts (NICS) as an aromaticity criterion to evaluate the antifungal activity of two series of indol-4-ones. A linear regression analysis of NICS and antifungal activity showed that both tested variables were significantly related (p –1 for Candida glabrata, Candida krusei and Candida guilliermondii with compounds 15-32, 15-15 and 15-1. The MIC for filamentous fungi was 1.95 μg·mL–1 for Aspergillus niger for compounds 15-1, 15-33 and 15-34. The results obtained support the use of NICS in the molecular design of compounds with antifungal activity.

Synthesis and preliminary photopolymerization evaluation of novel photoinitiators containing phototrigger to overcome oxygen inhibition in the UV- curing system

In this work, two types of novel photoinitiaors containing phototrigger were prepared to overcome oxygen inhibition in the UV- curing system in the absence of hydrogen donor. The structures of prepared novel photoinitiators were determined by nuclear magnetic resonance (NMR) and high resolution MS (HR[sbnd]MS) spectra data. The photo chemical behavior and photo-reactivity were also evaluated by ultraviolet-visible (UV–vis) spectroscopy and real-time Fourier transform infrared spectroscopy (RT-FTIR), respectively. The results show the prepared photoinitiators exhibit remarkable redshift compared to the commercial BP (benzophenone) and Irgacure 907 (2-methyl-1-(4-methylsulfanylphenyl)-2-morpholin-4-ylpropan-1-one), fast photolysis by C[sbnd]S bond, good photo initiation and significant overcoming oxygen inhibition for some compounds, which can be used as one-component photoinitiator candidates.

A medicine for treating diseases of the nervous system of the new compound

The invention belongs to the technical fields of medicines, and relates to compounds having a structure represented as a formula I and pharmaceutically acceptable salts of the compounds, wherein the R1 and R2 are selected from a group consisting of hydrog